Results 121 to 130 of about 1,056,746 (161)

Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China. [PDF]

open access: yesTher Adv Med Oncol
Guo Y   +11 more
europepmc   +1 more source

Agentic markets. [PDF]

open access: yesElectron Mark
Bichler M.
europepmc   +1 more source

Medicaid access to Most Favored Nation through the Pfizer agreement: The unanswered issues. [PDF]

open access: yesJ Manag Care Spec Pharm
Ballreich J   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy